Application
Fig1: Western blot analysis of LEF1 on human LEF1 recombinant protein using anti-LEF1 antibody at 1/1,000 dilution.Application
Fig2: Western blot analysis of LEF1 on HEK293 (1) and LEF1-hIgGFc transfected HEK293 (2) cell lysate using anti-LEF1 antibody at 1/1,000 dilution.Application
Fig3:Western blot analysis of LEF1 on different cell lysate using anti-LEF1 antibody at 1/1,000 dilution. Positive control： Lane1: Jurkat Lane2: HepG2 Lane3: MOLT4Application
Fig4: Immunohistochemical analysis of paraffin-embedded human?colon cancer tissue using anti-LEF1 antibody. Counter stained with hematoxylin.Application
Fig5: Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissue using anti-LEF1 antibody. Counter stained with hematoxylin.| Product Name | LEF1 [B11-A4] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | DKFZp586H0919 antibody FLJ46390 antibody LEF 1 antibody LEF-1 antibody Lef1 antibody LEF1_HUMAN antibody Lymphoid enhancer binding factor 1 antibody Lymphoid enhancer-binding factor 1 antibody T cell specific transcription factor 1 alpha antibody T cell-specific transcription factor 1-alpha antibody TCF 1 alpha antibody TCF1 alpha antibody TCF1-alpha antibody TCF10 antibody TCF1alpha antibody TCF7L3 antibody Transcription factor T cell specific 1 alpha antibody |
| Product description | The TCF (T cell factor) family of transcription factors are activated by the Wnt-1 and Wingless pathways and are characterized by the presence of a conserved protein motif, the high mobility group (HMG) 1 box, which mediates DNA binding. The TCF (T cell factor) proteins, which are required during development, include TCF-1, which is essential for lymphoid cell development, and TCF-3 and TCF-4, which are implicated in neuronal development and LEF (leukemia enhancer factor).The Wnt mediated signaling pathway induces cytosolic β-catenin binding to TCF proteins within the nucleus, leading to the enhanced expression of the Wnt target genes. The β-catenin-TCF complexes are negatively regulated by the adenomatous polyposis coli (APC) tumor suppressor protein, which phosphorylates β-catenin and, in turn, increases the degradation of cytosolic β-catenin to, thereby, inhibit the transcriptional activity of the TCF proteins. Mutations in the APC gene, which are commonly observed in colorectal carcinomas, disrupt this regulatory pathway and correlate to an accumulation of β-catenin and the increased activation of the TCF target genes. |
| Immunogen | Recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG1 |
| Host Species | Mouse |
| Tested Applications | WBIHC |
| WB:1:500-1:2,000 IHC:1:50-1:200 |
|
| Species Reactivity | Human |
| Concentration | 2mg/ml |
| Alternative Names | DKFZp586H0919 antibody FLJ46390 antibody LEF 1 antibody LEF-1 antibody Lef1 antibody LEF1_HUMAN antibody Lymphoid enhancer binding factor 1 antibody Lymphoid enhancer-binding factor 1 antibody T cell specific transcription factor 1 alpha antibody T cell-specific transcription factor 1-alpha antibody TCF 1 alpha antibody TCF1 alpha antibody TCF1-alpha antibody TCF10 antibody TCF1alpha antibody TCF7L3 antibody Transcription factor T cell specific 1 alpha antibody |
|---|---|
| Molecular Weight(MW) | 44 kDa |
| Cellular Localization | Nucleus. |
| SwissProt ID | Q9UJU2 |
|---|
Application
Fig1: Western blot analysis of LEF1 on human LEF1 recombinant protein using anti-LEF1 antibody at 1/1,000 dilution.
Application
Fig2: Western blot analysis of LEF1 on HEK293 (1) and LEF1-hIgGFc transfected HEK293 (2) cell lysate using anti-LEF1 antibody at 1/1,000 dilution.
Application
Fig3:Western blot analysis of LEF1 on different cell lysate using anti-LEF1 antibody at 1/1,000 dilution. Positive control： Lane1: Jurkat Lane2: HepG2 Lane3: MOLT4
Application
Fig4: Immunohistochemical analysis of paraffin-embedded human?colon cancer tissue using anti-LEF1 antibody. Counter stained with hematoxylin.
Application
Fig5: Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissue using anti-LEF1 antibody. Counter stained with hematoxylin.| Positive Control | Human LEF1 recombinant protein, LEF1-hIgGFc transfected HEK293 cell lysate, Jurkat, HepG2, MOLT4, human?colon cancer tissue, human esophageal cancer tissue. |
|---|---|
| Application Notes | WB:1:500-1:2,000 IHC:1:50-1:200 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
